Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells
- Zhaohui Wei1, 2,
- Naiyao Chen1Email author,
- Hongxing Guo2,
- Xueming Wang1,
- Fangyun Xu2,
- Qian Ren2,
- ShiHong Lu2,
- Bin Liu2,
- Lei Zhang2 and
- Hui Zhao1, 2Email author
© Wei et al. 2009
Received: 27 July 2009
Accepted: 03 November 2009
Published: 03 November 2009
The regulation of growth and apoptosis in K562 cells by human bone marrow mesenchymal stem cells (MSCs) from leukemia patients was investigated.
K562 cells were cocultured with leukemic MSCs under serum deprivation. Cell Counting Kit-8 (CCK-8), PI staining, Annexin V/PI binding and FACS assays were used to investigate cell proliferation, cell cycle status, and apoptosis of K562 cells cultures in the presence or absence of 10% serum. Western blotting was used to determine the levels of Akt, phosphorylated Akt (p-Akt), the BCL-2 family member Bad, and phosphorylated Bad (p-Bad) proteins in K562 cells after coculturing with MSCs. The effects of LY294002 (a specific inhibitor of PI3K) on protein expression were also determined.
K562 cell proliferation was inhibited by coculture with MSCs and the dominant cell cycle was the G0-G1 phase. The proportion of apoptotic K562 cells was decreased and the levels of p-Akt and p-Bad were upregulated after exposing K562 cells to MSCs. However, when LY294002 was used, p-Akt and p-Bad proteins inK562 cells showed a significant reduction, while no distinct variation was seen in the nonphosphorylated Akt and Bad protein levels.
Leukemic MSCs can inhibit K562 cell expansion and modulate the cell cycle to a state of relative quiescence. This allows the K562 cells to endure adverse conditions such as serum starvation. The PI3K-Akt-Bad signaling pathway may be involved in this antiapoptotic process via phosphorylation of the Akt and Bad proteins. Blocking MSC-induced transduction of the PI3K-Akt-Bad pathway may be a potential strategy for a targeted therapy to combat leukemia.
Bone marrow is not only the source of leukemic cells, but is also the primary site of leukemia relapse . For these reasons, the hematopoietic microenvironment (HM) of the bone marrow plays a crucial role in the development and progression of leukemia. Variations in the HM may influence the biological behaviors of leukemia cells; for example, induction of resistance to chemotherapy drugs by hypoxia  is now known to involve many components. One important HM component is the bone marrow mesenchymal stem cell (MSC), which is involved in stabilizing microenvironments, and forming niches for cancer cells to endure adverse conditions.
Investigators have demonstrated normal MSCs and established MSC cell lines can protect leukemia cells from apoptosis [3–5]. However, the role of leukemic MSCs in the pathogenesis and prognosis of leukemia are still not well elucidated. What is known is that a substantial number of MSCs from leukemia patients are likely to differentiate into malignant cells and it is these cells that play multiple roles in directly regulating leukemia cells. However, the possibility that MSCs from patients with leukemia possess similar ability to modulate leukemia cells has not been well explored. Leukemic MSCs in all probability will aid in cell survival under adverse conditions (e.g., hypoxia, chemotherapy, serum deprivation). For this reason, we have designed a system that mimics a serum deprivation condition (i.e., fetal bovine serum (FBS) starvation) in order to observe the status of K562 cells and the influence of leukemic MSCs upon them.
The PI3K-Akt signal pathway and its downstream target BCL-2 family members play important roles in the induction and regulation of cell apoptosis, survival, proliferation and formation of the cellular framework . Many studies have shown that activation of this signaling pathway in some leukemia cells continues for an extended duration [7–9]. An uncertain relationship still exists between the PI3K-Akt pathway and MSCs. Hence, the aim of the present study was to provide a preliminary outline of the variations of key proteins involved in the PI3K-AKt signaling pathway in leukemia cells.
Materials and methods
Human chronic myelogenous leukemia cell line K562 was maintained in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 U/ml streptomycin and 0.2 mmol/L glutamine at 37°C in a humidified incubator with a 5% CO2 atmosphere. Prior to the experiments, the K562 cells were suspended in complete DF-12 medium (Gibco, containing 10% FBS, 100 U/ml penicillin, 100 U/ml streptomycin and 0.2 mmol/L glutamine) or in DF-12 medium without serum.
Isolation and characterization of human leukemic mesenchymal stem cells (MSCs)
Heparinized bone marrow from each patient (4 patients: 2 with chronic myelogenous leukemia in blast crisis, 1 with acute myelogenous leukemia, and 1 with acute lymphoblastic leukemia) was obtained after informed consent. The marrow was diluted twice with phosphate buffered saline (PBS), then isolated by Ficoll-Hypaque (Institute of Hematology) density-gradient centrifugation. Monocytes were collected by adherence to a plastic flask and incubated for 48 hrs in MSC conditioned medium containing 10% FBS, 0.2 mmol/L glutamine, 10-9 M Dex, 10 ng/ml EGF, 100 U/ml penicillin and 100 U/ml streptomycin. Medium was replaced at least twice a week and nonadherent cells were discarded. After 3-5 passages, the cells met the minimal criteria for defining multipotent mesenchymal stromal cells  with typical CD34-, CD14-, HLA-DR-, CD73+, CD90+, and CD105+, as identified by flow cytometry (data not shown). Fluorescein isothiocyanate labeled antibodies for the MSC immunophenotype were purchased from BD Pharmingen, except for CD105 antibody, which was phycoerythrin-labeled and purchased from Serotec. When MSCs were 80%-90% confluent, they were digested with trypsin and resuspended with MSC conditioning medium (supplemented with or without 10% serum) in preparation for experiments.
Coculturing modifications for observing proliferation of K562 cells
Simple culture group (SCG group)
This group was divided into two subgroups based on culture media used. The SCG-N group represented the K562 cells cultured in completed DF-12 medium containing 10% FBS. The SCG-S group represented the K562 cells in DF-12 medium without serum. Both subgroups were cultured at 37°C in a humidified incubator with a 5% CO2 atmosphere for 72 hrs.
Contact culture group (CCG group)
MSCs were seeded into 24-well plates (Costar, Bodenheim, Germany) at the initial density of 1 × 104 cells/well, or 1 × 105 cells/well in 6-well plates (Costar, Bodenheim, Germany), and maintained in a 5% CO2, humidified atmosphere at 37°C for 24 hrs. The cells were then given a total gamma-irradiation of 15 Gy. Subsequently, K562 were seeded at 105 cells/well and cocultured with MSCs in 24-well plates for 24, 48 or 72 hrs. The K562:MSC ratio was 10:1, was selected according to previous literature. The medium was supplemented with (CCG-N group) or without (CCG-S group) 10% FBS.
Separately cocultured group (Transwell group)
MSCs (1 × 104 initial cell count) were cultured for 24 hrs in the upper side of a transwell (NUNC Company, Denmark) chamber partitioned by a polycarbonate membrane (8.0 μm pore size, Corning Incorporated, Costar). These MSCs were then given a total irradiation of 15 Gy. After discarding the supernatant, the MSCs were cocultured with 1 × 105 of K562 cells in the lower part in DF-12 medium (with or without 10% FBS) at 37°C, 5% CO2 for 72 hrs.
Preparation for the conditioned medium group
MSCs were cultured in complete DF-12 medium at 37°C, 5% CO2 for 72 hrs, then the culture medium was harvested and centrifuged at 2,000 rpm for 10 min and stored at -80°C. This medium was doubled diluted with DF-12 medium without FBS then used to culture K562 cells for 72 hrs. The CM group included two subgroups cultured in conditioned medium with or without FBS.
CCK-8 assay for detecting proliferation of K562 cells
Cells from the SCG, CCG, Transwell, and CM groups were cultured in DF-12 media with or without FBS for further observation. When cells were cocultured in different media for 72 hrs, cell proliferation was measured with a Cell Counting Kit-8 (Dojindo, Shanghai), following the manufacturer's instructions.
Propidium iodide (PI) flow cytometric assay for determining cell cycle status under different nutritional states
The PI staining method was used for detecting the cell cycle status of cells of the SCG-N, CCG-N and CCG-S groups, using the manufacturer's protocol. Briefly, DNA was stained with 50 μg/ml propidium iodide (Sigma). Samples were kept for 1 hr in the dark at room temperature and the DNA index was then measured by cytofluorimetric analysis using an FACS Calibur flow cytometer (Becton Dickinson, San Diego, CA). Data were analyzed using CellQuest software.
Annexin V/PI for cell apoptotic analysis
Cell viability was detected by trypan blue and apoptosis was evaluated by the annexin V/propidium iodide (BD Biosciences) double staining assay following the manufacturer's instructions. K562 cells were harvested at the end of treatment, rinsed twice with PBS, and stained with Annexin V-FITC apoptosis detection kit I (BD Biosciences). Analysis was performed on the FACS Calibur using CellQuest software.
Three groups of K562 cells were cultured at 37°C, 5% CO2 for 24 hrs. SCG-S represented the group of K562 cells cultured without FBS. CCG-S represented the group of K562 and MSCs without FBS. CCG-S+LY294002 represented the group pretreated with 10 μM LY294002 for 1 hr. After incubation, K562 cells were dissolved in lysis buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerin, 200 mM dithiothreitol, plus protease inhibitors) and quantified for proteins by a BCA protein assay kit (Pierce Company, USA). Equal amounts of protein extract were loaded onto a 12% SDS-PAGE gel and transferred to PVDF membrane (Gibaino Company, Beijing, China). The blot was blocked in 5% fat-free milk at 4°C overnight and then incubated with mouse monoclonal anti-Akt, p-Akt-Ser-473, anti-Bad, p-Bad-Ser-136 antibodies, (Cell Signal Transduction). Mouse monoclonal anti-beta-actin antibody (Cell Signal Transduction) was used as control. The immunocomplexes were visualized by using a chemiluminescent kit (Cell Signal Transduction).
Data were presented as mean ± SD, using the SPSS system package for statistical analysis. Student-t-test was used for comparison of two groups of data. One-Way ANOVA was used for more than two groups of data. Multiple comparisons between two groups were analyzed by a SNK-q test. A P value < 0.05 was considered significant.
MSCs inhibit proliferation of K562 cells under different nutritional conditions
Effects of MSCs on K562 cell cycles
Effects of MSCs on the apoptosis of K562 cells
Effects of MSCs on protein expression in K562 cells
As shown in figure 4B, a band at 23 KD, representing the Bad and p-Bad proteins in K562 cells, also showed obvious increases in the phosphorylated form of Bad in the CCG-S group. Upregulation was nearly reversed by treatment with LY294002, which causes an upstream blockade of PI3K. There were no significant variations among the Bad levels of these groups.
As evidence on bone marrow HM has accumulated over the past few years, it has become widely acknowledged that MSCs affect a great number of different cell types besides hematopoietic parenchymal cells, including leukemia cells [11–13]. With this close relationship between MSCs and leukemia cells, it may be that the influence of MSCs is what ultimately determines the prognosis of leukemia.
In general, MSCs in the HM have been considered to be nurse-like cells that exert a form of protective modulation. Leukemic MSCs can reportedly inhibit the chemotherapeutic-induced apoptosis of Jurkat cells and HL-60 cells. Moreover, they can interfere with the cell cycle of Jurkat cells at the G0-G1 phase [14, 15]. They can also negatively regulate cancer immunotherapy involving NK cells and inhibit cytotoxic T cells by secreting cytokines [16, 17]. Thus, there appear to be multiple roles of MSCs in proliferation, differentiation, and survival of leukemia cells [18–20] as well as normal immune cells. In the present study, the role of leukemic MSCs on K562 cells was explored under normal nutritional conditions or under serum starvation. We noticed a marked increase in K562 cell apoptosis after serum starvation for 24 hours. However, a marked decrease in apoptosis was observed when these starved cells were cocultured with MSCs, supporting the protective role of leukemic MSCs against apoptosis. This inhibition existed both in contact coculture and in separated coculture, and was induced even by supernatant culture medium from MSCs. Thus, our data support that cytokines, adherent reactions and gap junctions participated in inhibiting leukemic cell proliferation.
When K562 cells were cocultured with normal MSCs, they also showed cell cycle blockade. These K562 cells also showed drug-resistance to daunorubicin (DNR), which is consistent with their increased G0-G1 phase and reduced S phase. The reasons for this drug resistance may also relate to the upregulation of antiapoptotic gene expression and the cytokines secreted by MSCs. Our data also showed a similar cell cycle blockade of K562 cells resulting from coculture with leukemic MSCs obtained from 4 patients, although these nurse cells may have undergone malignant transformation in vivo or over their long time in culture. Inhibition of cell growth is a primary method of treating leukemia; however, the blockade of the cell cycle may prevent the efficacy of chemotherapeutic agents, which mainly target the proliferative phase of tumor cells. When most tumor cells are blocked at the quiescent phase, they may evade the killing powers of chemotherapeutics and may ultimately form micro residual disease (MRD). We hypothesize that leukemic MSCs may provide a niche for tumor stem cells, in which K562 cells back up the proliferation and self-renewal potential. These tumor cells may then be the source of relapse.
Constitutive activation of Akt, one downstream target of PI3K, is also believed to promote proliferation and increase cell survival, leading to cancer progression. The PI3K-Akt signal pathway is involved in the antiapoptotic activity of tumor cells and culminates in the phosphorylation of the BCL-2 family member, Bad, thereby suppressing apoptosis and promoting cell survival. Akt phosphorylates Bad both in vitro and in vivo, and blocks Bad-induced cell death . The PI3K-Akt-Bad pathway may represent a form of general antiapoptotic machinery, although there is insufficient evidence to support this hypothesis at present.
We determined the expression levels of Akt, p-Akt, Bad, p-Bad proteins in K562 cells after inoculation with MSCs. Under the condition of K562 cells alone, there was a basal expression of p-Akt, and p-Bad, which might have been related to the bcr/abl fusion protein-activated PI3K-Akt signal pathway. In addition, the expression of p-Akt and p-Bad was increased after coculture with leukemic MSCs. The addition of the specific inhibitor LY294002, which competes with PI3K for ATP binding sites , resulted in a dramatic decrease in levels of both phosphorylated proteins, while no obvious difference in Akt and Bad expression was observed among the three groups. Hence, we showed that the PI3K-Akt pathway was activated after coculture with MSCs. The pro-apoptotic molecule, Bad, was then phosphorylated and exerted inhibitory effects on starvation-induced apoptosis.
Taken together, serum deprivation appears to mimic the effects of an adverse HM for leukemia cells. MSCs of leukemia patients can retard the cell cycles of K562 cells, inhibiting their proliferation and reducing their apoptosis. Consequently, MSCs protect leukemia cells against adverse conditions like serum deprivation and ultimately sustain their viability. The activation of the PI3K-Akt-Bad signaling pathway seems to be involved in the protective machinery. Therefore, approaches that block the activation of this signaling pathway may in turn remove this shielding and consequently may prove to be of benefit in the effective treatment of leukemia.
This work is supported by grants of 863 projects from the Ministry of Science & Technology of China (2006AA02A110 for H.Z, L.Z), the Projects from National Natural Science Foundation of China(30700285 for B.L, Z.H.W, N.Y.C, and 30600238 for L.Z, S.H.L, Q.R), and the projects from Tianjin Municipal Science and Technology Commission(06YFSZSF01300 for B.L, L.Z, H.Z, and 07JCYBJC11200 for L.Z, B.L).We thank the EasyStar company http://essaystar.com/ for their excellent English language editing.
- Goulden N, Langlands K, Steward C, Katz F, Potter M, Chessells J, Oakhill A: PCR assessment of bone marrow status in "isolated" extramedullary relapse of childhood B-pre-cursor acute lymphoblastic leukemia. Br J Hematol 1994, 87: 282–5.View Article
- Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J: Hypoxia-induced resistance to cisplatin and doxorubicin in nonsmall cell lung cancer is inhibited by silencing of HIF-1α gene. Cancer Chemotherapy and Pharmacology 2006, 58: 776–84.View ArticlePubMed
- Gibson LF: Survival of B lineage leukemic cells: signals from the bone marrow microenvironment. Leuk Lymphoma 2002, 43: 19–27.View ArticlePubMed
- Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M: Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 2007, 67: 684–94.View ArticlePubMed
- Wang L, Fortney JE, Gibson LF: Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk Res 2004, 28: 733–42.View ArticlePubMed
- Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M: Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16: 1713–24.View ArticlePubMed
- Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M: Survival of acute myeloid leukemia cells requires PI3-kinase activation. Blood 2003, 102: 972–80.View ArticlePubMed
- Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T: Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells:direct evidence of PI3K activation. Leukemia 2004, 18: 1438–40.View ArticlePubMed
- Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS, Ko YW: Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003, 17: 995–7.View ArticlePubMed
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8: 315–7.View ArticlePubMed
- Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F: Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007, 21: 304–10.View ArticlePubMed
- Asosingh K, Günthert U, Bakkus MH, De Raeve H, Goes E, Van Riet I, Van Camp B, Vanderkerken K: In vivo induction of insulin-like growth factor-1 receptor and CD44v6 confers homing and adhesion to murine multiplemyeloma cells. Cancer Res 2000, 60: 3096–104.PubMed
- Shimakura Y, Kawada H, Ando K, Sato T, Nakamura Y, Tsuji T, Kato S, Hotta T: Murine stem cell line HESS-5 maintains reconstituting ability of ex vivo generated hematopoietic stem cells from human bone marrow and cytokine-mobilized peripheral blood. Stem Cells 2000, 18: 183–9.View ArticlePubMed
- Koller MR, Oxender M, Jensen TC, Goltry KL, Smith AK: Direct contact between CD34+ lin-cells and stroma induces a soluble activity that specifically increases primitive hematopoietic cell production. Exp Hematol 1999, 27: 734–41.View ArticlePubMed
- Zhang X, Wang P, Cheng XH, Liu L, Peng XG, Wang QY, Kong PY, Liu H, Zhang y, Gao L, Zhong YM: Effects of leukemia bone marrow stem cells on resistance of co-cultured HL-60 to Idarubicin. J Exp Hematol 2004, 12: 163–5. (article in Chinese)
- Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M: Intera ctions Between Human Mesenchymal Stem Cells and Natural Killer Cells. Stem Cells 2006, 24: 74–85.View ArticlePubMed
- Rasmusson I, Ringdén O, Sundberg B, Le Blanc K: Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76: 1208–13.View ArticlePubMed
- Granziero L, Circosta P, Scielzo C, Frisaldi E, Stella S, Geuna M, Giordano S, Ghia P, Caligaris-Cappio F: CD100/plexin B1 interactions sustain proliferation and sur vival of normal and leukemia CD5 + B lymphocyte. Blood 2003, 101: 1962–9.View ArticlePubMed
- Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, Kato J, Hirayama Y, Sakamaki S, Kohda K, Miyake K, Niitsu Y: Interaction between leukemic cell VLA-4 and stem fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9: 1158–65.View ArticlePubMed
- Paraguassú-Braga FH, Borojevic R, Bouzas LF, Barcinski MA, Bonomo A: Bone marrow stem inhibits proliferation and apoptosis in leukemic cells through gap junction mediated cell communication. Cell Death Differ 2003, 10: 1101–8.View ArticlePubMed
- Cheng ZY, Guo XL, Yang XY, Niu ZY, Li SH, Wang SY, Chen H, Pan L: PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. Journal of Experimental & Clinical Cancer Research 2008, 27: 87.View Article
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery. Cell 1997, 91: 231–41.View ArticlePubMed
- Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phospha-tidylin ositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY 294002). J Biol Chem 1994, 269: 5241–8.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.